Zeposia (ozanimod) is an oral sphingosine-1 phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
If you have a Hayes login, click here to view the full report on the Knowledge Center.